Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMNM Immunome	$17.18 -1.2%	$23.03	$4.44 ▼ $30.96	$1.03B	1.66	699,043 shs	852,654 shs
LCI Lannett		$1.54	$0.64 ▼ $3.72	$7.38M	0.95	92,067 shs	280,600 shs
OPTN OptiNose	$0.93 -8.8%	$1.51	$0.90 ▼ $2.10	$104.51M	-0.24	534,927 shs	548,193 shs
SBBP Strongbridge Biopharma	$2.00	$2.09	$1.85 ▼ $4.26	$135.66M	1.58	866,464 shs	684,684 shs
VYNE VYNE Therapeutics	$2.30 -4.2%	$2.42	$1.67 ▼ $8.73	$32.43M	1.23	122,275 shs	11,091 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMNM Immunome	-1.15%	-18.27%	-28.65%	+27.26%	+209.55%
LCI Lannett	0.00%	0.00%	0.00%	0.00%	0.00%
OPTN OptiNose	-9.05%	-25.19%	-46.06%	-31.79%	-52.67%
SBBP Strongbridge Biopharma	0.00%	0.00%	0.00%	0.00%	0.00%
VYNE VYNE Therapeutics	-4.17%	-23.33%	+10.05%	+29.21%	-48.43%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMNM Immunome	1.6163 of 5 stars	3.5	0.0	0.0	0.0	3.2	1.7	0.0
LCI Lannett	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.0841 of 5 stars	3.5	3.0	0.0	4.2	0.0	2.5	0.6
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.6432 of 5 stars	3.5	3.0	0.0	0.0	2.3	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMNM Immunome	3.00	Buy	$32.67	90.14% Upside
LCI Lannett	N/A	N/A	N/A	N/A
OPTN OptiNose	3.00	Buy	$4.00	331.17% Upside
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	3.00	Buy	$7.38	220.65% Upside

Current Analyst Ratings

Latest OPTN, LCI, IMNM, SBBP, and VYNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	IMNM Immunome	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
4/1/2024	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $33.00
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00
2/29/2024	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.75
1/29/2024	IMNM Immunome	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
1/29/2024	IMNM Immunome	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
1/23/2024	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $19.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMNM Immunome	$14.02M	73.14	N/A	N/A	$2.77 per share	6.20
LCI Lannett	$340.58M	0.00	N/A	N/A	($23.34) per share	0.00
OPTN OptiNose	$70.99M	1.47	N/A	N/A	($0.77) per share	-1.20
SBBP Strongbridge Biopharma	$30.73M	4.41	N/A	N/A	$0.98 per share	2.04
VYNE VYNE Therapeutics	$420K	77.21	N/A	N/A	$6.36 per share	0.36

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMNM Immunome	-$106.81M	-$5.39	N/A	N/A	N/A	-761.92%	-69.74%	-31.40%	5/3/2024 (Estimated)
LCI Lannett	-$231.62M	-$18.88	N/A	N/A	N/A	-62.40%	N/A	-13.39%	N/A
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)
SBBP Strongbridge Biopharma	-$45.08M	-$0.78	N/A	N/A	N/A	-115.67%	-66.82%	-36.21%	N/A
VYNE VYNE Therapeutics	-$28.45M	-$7.04	N/A	N/A	N/A	-6,710.38%	-77.46%	-62.93%	5/9/2024 (Estimated)

Latest OPTN, LCI, IMNM, SBBP, and VYNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million
2/29/2024	Q4 2023	VYNE VYNE Therapeutics	-$0.50	-$0.20	+$0.30	-$0.20	$0.15 million	$0.08 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
SBBP Strongbridge Biopharma	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMNM Immunome	N/A	6.63	6.63
LCI Lannett	N/A	2.23	1.39
OPTN OptiNose	N/A	0.60	0.55
SBBP Strongbridge Biopharma	0.38	3.00	2.95
VYNE VYNE Therapeutics	N/A	12.73	12.73

Ownership

Institutional Ownership

Company	Institutional Ownership
IMNM Immunome	44.58%
LCI Lannett	40.28%
OPTN OptiNose	85.60%
SBBP Strongbridge Biopharma	52.03%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
IMNM Immunome	20.00%
LCI Lannett	13.12%
OPTN OptiNose	2.20%
SBBP Strongbridge Biopharma	5.10%
VYNE VYNE Therapeutics	1.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
IMNM Immunome	37	59.69 million	47.76 million	Optionable
LCI Lannett	810	10.77 million	9.35 million	Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable
SBBP Strongbridge Biopharma	72	67.83 million	N/A	Optionable
VYNE VYNE Therapeutics	10	14.10 million	13.85 million	Not Optionable

OPTN, LCI, IMNM, SBBP, and VYNE Headlines

Source	Headline
	VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - April 13 at 8:27 AM
	Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 590.3% americanbankingnews.com - April 11 at 2:54 AM
	Acne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032 pharmiweb.com - March 28 at 12:46 PM
	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference finance.yahoo.com - March 19 at 9:08 AM
	VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference globenewswire.com - March 19 at 8:00 AM
	Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now zacks.com - March 13 at 10:56 AM
	What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock zacks.com - March 8 at 1:01 PM
	Wall Street Breakfast Podcast: NYCB Gets $1B Investment Boost seekingalpha.com - March 7 at 8:21 AM
	VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 3 at 8:59 AM
	Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments markets.businessinsider.com - February 29 at 7:00 PM
	VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update finanznachrichten.de - February 29 at 10:04 AM
	VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update globenewswire.com - February 29 at 8:00 AM
	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium finance.yahoo.com - February 27 at 8:06 AM
	VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium globenewswire.com - February 27 at 8:00 AM
	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference finance.yahoo.com - February 21 at 8:16 AM
	VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference globenewswire.com - February 21 at 8:00 AM
	Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock finance.yahoo.com - February 2 at 7:18 AM
	Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results markets.businessinsider.com - January 10 at 4:27 PM
	Prurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Study fmiblog.com - January 4 at 12:32 AM
	VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors finance.yahoo.com - January 3 at 9:29 AM
	Investing in VYNE Therapeutics Inc [VYNE]: What You Must Know knoxdaily.com - January 1 at 10:15 AM
	VYNE Therapeutics says director Lepore buys 13K shares in co msn.com - November 20 at 3:25 PM
	Cormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Inc finance.yahoo.com - November 14 at 5:53 PM
	VYNE Therapeutics files to sell 36.27M shares for holders msn.com - November 13 at 5:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Immunome

NASDAQ:IMNM

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Lannett

NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Strongbridge Biopharma

NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

VYNE Therapeutics

NASDAQ:VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial